Adamas Pharma Stock Analysis, Valuation (NASDAQ:ADMS)

Add to My Stocks
$31.88 $0.79 (2.42%) ADMS stock closing price May 18, 2018 (Closing)
Watch Robo Advisor Video of ADMS Stock Analysis
Adamas Pharma
Updated on : May 18, 2018
previous close
ADMS 31.9 (0%)
S&P 500 2713 (0%)
Closing Price On: May 18, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Generic Drugs
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Operating Margins
Net Margins
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Adamas Pharma Stock Analysis

45 5 2

Take a look at Amigobulls Adamas Pharma stock analysis video. This video puts forward our latest analysis highlighting the pros and cons for ADMS stock.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Adamas Pharmaceuticals Inc Stock Rating 1.9/5

We at Amigobulls use various financial measures including profit margins, revenue growth and dividends for ADMS stock analysis. We compare Adamas Pharma valuation with its sector peers to gauge relative attractiveness of ADMS stock. Based on a company's historical fundamentals we arrive at Adamas Pharma stock rating which is indicative of the company's financial performance.

Should you buy ADMS stock?

Should you sell ADMS stock?

  • Adamas Pharma sales declined by -999% year on year in 2018 Q1.
  • Adamas Pharma reported an average operating margin of -3292% over the Last Twelve Months (LTM).
  • Adamas Pharma registered an average TTM Net loss of -3475.6%.
  • With a debt/equity ratio of  0.63, Adamas Pharma is highly leveraged in comparison to Medical peers.
  • PE ratio is meaningless for ADMS stock as the company has losses.
  • The company is trading at a price to sales multiple of 264.2, which is higher in comparison to the Medical-Generic Drugs industry average of 6.4, making ADMS stock expensive.
  • The company has a negative Return on Invested Capital of -549.1%, which is a red flag.
  • Adamas Pharma has a negative return on equity of -99.4%. This indicates that the firm is inefficient at generating profits.
  • The company has a negative free cash flow margin of -992.2%.

Comments on this video and Adamas Pharma stock

Amigobulls Adamas Pharma stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of ADMS stock. Company's fundamentals remain one of the key driver of ADMS stock and helps investors in making good buy and sell decision.

Adamas Pharma revenue growth is an indicator of the demand for a company's products while profit margin is indicative of company's pricing power and pricing strategy. One can also combine technical analysis and fundamental analysis to get a holistic picture about ADMS stock.